DFTX — Definium Therapeutics, Inc.
—
Nasdaq ·
Materials ·
Chemicals ·
CIK 1813814 ·
Last close
$43.27
Market Cap
$5.81B
52W High
$49.70
52W Low
$21.69
ADV30
2,027,012
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -75,077,000 | -158,986,000 | 1,112,899,000 | 655,267,000 | 194,220,000 |
| Mar 2026 | 0 | — | -59,220,000 | -77,098,000 | 401,293,000 | 262,518,000 | 122,444,000 |
| Dec 2025 | 0 | — | -47,578,000 | -50,436,000 | 440,100,000 | 257,837,000 | 107,773,000 |
| Sep 2025 | 0 | — | -45,669,000 | -67,265,000 | 236,916,000 | 19,959,000 | 106,320,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-144,772,000
Investing CF
$52,852,000
Financing CF
$271,576,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.34
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-659,770,000
Inventory
—
Receivables
—
ST Investments
$110,904,000
EBIT TTM
$-231,418,000
Pretax Income TTM
$-237,543,000
Interest Exp TTM
$6,125,000
Analysts
16
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -166,309,000 | -183,793,000 | 440,100,000 | 107,773,000 | — | -131,560,000 |
| Dec 2024 | 0 | -103,916,000 | -108,679,000 | 302,151,000 | 60,703,000 | — | -79,129,000 |
| Dec 2023 | 0 | -93,866,000 | -95,732,000 | 124,541,000 | 46,407,000 | — | -64,365,000 |
| Dec 2022 | 0 | -66,331,000 | -56,796,000 | 169,993,000 | 19,076,000 | — | -50,139,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.88
Max Pain — expiry 2026-09-18
max pain strike: $40.00 · spot: $43.27 · call oi: 21,209 · put oi: 6,264
Expected Move to 2026-09-18:
±$7.40
(17.10%) —
implied range
$35.87 –
$50.67
· ATM straddle on $43.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SXT | SENSIENT TECHNOLOGIES CORP | $5.85B | $137.45 | — |
| BCPC | BALCHEM CORP | $5.66B | $177.50 | — |
| ELF | e.l.f. Beauty, Inc. | $6.25B | $105.95 | — |
| CSW | CSW INDUSTRIALS, INC. | $5.34B | $327.56 | — |
| PRM | Perimeter Solutions, Inc. | $5.02B | $30.66 | — |
News headlines (Yahoo Finance, 1h cache)
Definium Therapeutics Announces New Employee Inducement Grants
2026-08-17 20:01 · Yahoo
Definium Therapeutics (DFTX) Voyage Data Puts Valuation Back In Focus
2026-08-14 06:10 · Yahoo
Definium Therapeutics (DFTX) Hits Phase 3 GAD Goals For DT120 ODT
2026-08-13 17:11 · Yahoo
Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says
2026-08-13 15:44 · Yahoo
Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study
2026-08-13 10:04 · Yahoo
Definium Scores Another Win For Its LSD-Based Drug. Shares Pop.
2026-08-12 20:06 · Yahoo
DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’
2026-08-12 17:06 · Yahoo
Definium Therapeutics shares surge after positive Phase 3 anxiety trial results
2026-08-12 12:01 · Yahoo
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
2026-08-12 11:00 · Yahoo
DFTX Stock On Track For Worst Day In 9 Months As Investors Brace For Anxiety Trial Data
2026-08-11 17:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.